Trial Profile

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danvilostomig (Primary)
Indications Adenocarcinoma; Gastric cancer; Malignant-mesothelioma; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Sponsors Sichuan Baili Pharmaceutical

15 Oct 2024 Planned End Date changed from 1 Aug 2024 to 1 Jun 2025.
15 Oct 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Jun 2025.
27 Jun 2024 Planned End Date changed from 1 May 2024 to 1 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com